Pfizer Inc. (NYSE:PFE) Shares Purchased by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,230,300 shares of the biopharmaceutical company’s stock after acquiring an additional 46,200 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $59,170,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New York Life Investment Management LLC grew its stake in shares of Pfizer by 1.2% in the 4th quarter. New York Life Investment Management LLC now owns 786,520 shares of the biopharmaceutical company’s stock valued at $20,866,000 after purchasing an additional 9,007 shares during the last quarter. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $231,000. Cable Hill Partners LLC lifted its holdings in shares of Pfizer by 20.5% in the 4th quarter. Cable Hill Partners LLC now owns 21,344 shares of the biopharmaceutical company’s stock valued at $566,000 after buying an additional 3,632 shares during the period. Whipplewood Advisors LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $108,000. Finally, Corrado Advisors LLC grew its holdings in Pfizer by 15.2% during the fourth quarter. Corrado Advisors LLC now owns 70,974 shares of the biopharmaceutical company’s stock worth $1,883,000 after acquiring an additional 9,357 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.40 on Thursday. The business has a fifty day simple moving average of $26.34 and a 200-day simple moving average of $27.36. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a market cap of $149.63 billion, a P/E ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. Pfizer’s payout ratio is currently 121.99%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.